Millipore Acquires Technology for Developing Antibodies

Millipore Corporation (Billerica, MA, USA) announced that it has purchased the assets associated with Epitome Biosystems' (Waltham, MA, USA) EpiTag technology. The purchase will accelerate development of multiplex immunoassays for cell signaling. Financial details were not disclosed.

The EpiTag technology uses a bioinformatics-driven approach to develop high quality antibodies that are more specific and selective than other reagents currently on the market. Using the EpiTag technology, Millipore expects to develop a new range of multiplex immunoassay kits that will enable scientists to more efficiently measure, detect, and analyze proteins and cell signaling pathways.

The purchase will enable Millipore's Bioscience division to expand its presence in the fast growing multiplex immunoassay market, by offering scientists a broader portfolio of cell signaling assays that can be used with the company's Luminex xMAP platform. Additionally, the acquisition will allow for the future development of other novel profiling technologies.

Millipore is one of the industry's pioneers in developing multiplex kits and reagents, and is a leader in providing assays for markets such as immunology, inflammation, and metabolic diseases (diabetes, obesity, cardiovascular). The company's Milliplex Map assays provide scientists with the sensitivity, specificity, and reproducibility they require to tackle complex problems.

Epitome Biosystems, Inc. develops and commercializes innovative protein measurement products and services to increase the productivity of drug discovery and development. The company's products generate valuable information about the cell-signaling network, which is a key interface for monitoring drug action and understanding disease.

Related Links:
Millipore Corporation
Epitome Biosystems